New Anticoagulants

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial

(2010) Michael Rud Lassen et al.   LANCET

Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran

(2009) Michael D. Ezekowitz et al.   AMERICAN HEART JOURNAL

AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery - TREK: a dose-ranging study

(2009) M. R. LASSEN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026

(2009) C. VISKOV et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Otamixaban in acute coronary syndromes

(2009) John W Eikelboom et al.   LANCET

Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial

(2009) Marc S Sabatine et al.   LANCET

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial

(2009) Alexander GG Turpie et al.   LANCET

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism

(2009) Sam Schulman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement

(2009) Michael Rud Lassen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Parenteral Anticoagulants

(2008) Jack Hirsh et al.   CHEST

New Antithrombotic Drugs

(2008) Jeffrey I. Weitz et al.   CHEST

Pharmacology and Management of the Vitamin K Antagonists

(2008) Jack Ansell et al.   CHEST

Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range

(2008) Stuart J. Connolly et al.   CIRCULATION

Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease

(2008) Mark Y. Chan et al.   CIRCULATION

Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development

(2008) Bengt I Eriksson et al.   CLINICAL PHARMACOKINETICS

Oral Thrombin Inhibitor Dabigatran Etexilate vs North American Enoxaparin Regimen for Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery

(2008)   JOURNAL OF ARTHROPLASTY

Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy

(2008) P. SAVI et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial

(2008)   LANCET

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

(2008) Ajay K Kakkar et al.   LANCET

Outbreak of Adverse Reactions Associated with Contaminated Heparin

(2008) David B. Blossom et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bivalirudin during Primary PCI in Acute Myocardial Infarction

(2008) Gregg W. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty

(2008) Bengt I. Eriksson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty

(2008) Michael R. Lassen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty

(2008) Neil Roskell et al.   THROMBOSIS AND HAEMOSTASIS